Tvardi Therapeutics, Inc.
TVRD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.11M
Close$
$2.64
197.4% upside
Current Fair Value
197.4% upsideUndervalued by 197.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.11 Million |
|---|---|
| Enterprise Value | $-7,509,447.00 |
| Earnings per Share | $-2.46 |
| Beta | 0.37 |
| Outstanding Shares | 9,357,000 |
Return
| Return on Equity | -366.69% |
|---|---|
| Return on Assets | -175.46% |
| Return on Invested Capital | -380.41% |
Valuation & Multiples
| P/E Ratio | -0.37 |
|---|---|
| PEG | 0.14 |
| Price to Sales | -0.89 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.92 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.70
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.55
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 23.81%▼ 5.00% |
|---|---|
| Total Invested | $4.25M▼ 50.61% |
| Investors Holding | 59▼ 7.00% |
About Cara Therapeutics Inc
12 employees
CEO: Derek Chalmers
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and...